曲妥珠单抗辅助治疗早期HER2阳性乳腺癌的药物经济学评价

发布时间：2018-03-24 05:29

本文选题：曲妥珠单抗HER阳性　切入点：乳腺癌　出处：《中国卫生经济》2017年11期

【摘要】：目的:从医疗保障部门角度对曲妥珠单抗辅助治疗早期HER2阳性乳腺癌进行药物经济学评价,为推进乳腺癌规范诊疗和医保政策制定提供依据和参考。方法:基于HERA临床试验,运用Markov模型模拟乳腺癌的发展,比较早期乳腺癌曲妥珠单抗1年辅助治疗组与观察组的成本效用,并进行经济学分析。结果:若采用曲妥珠单抗辅助治疗,患者的期望生存年、质量调整生命年将分别延长4.30年、2.86年,延长1年所需增加的医疗费用分别为96 334元、144 936元。结论:在湖北省使用曲妥珠单抗辅助治疗早期HER2阳性乳腺癌具有较好的成本效用,湖北省或经济发展水平相当及较高的省市医保部门可以考虑将曲妥珠单抗纳入到医保目录。
[Abstract]:Objective: to evaluate the pharmacoeconomics of trotozumab in adjuvant treatment of early HER2 positive breast cancer from the point of view of medical security department, so as to provide the basis and reference for the standard diagnosis and treatment of breast cancer and the formulation of medical insurance policy. Methods: based on the HERA clinical trial, The Markov model was used to simulate the development of breast cancer and to compare the cost-effectiveness of the treatment group with that of the observation group. Results: if tratozumab was used as adjuvant therapy, the patients' expected survival years were higher than that of the control group. The life years of quality adjustment will be extended by 4.30 years, 2.86 years and one year respectively, and the medical costs will be increased by 96 334 yuan or 144 936 yuan respectively. Conclusion: the adjuvant treatment of early HER2 positive breast cancer with tratozumab in Hubei Province has a good cost effect. Health care departments in Hubei province or other provinces and cities with similar economic development level may consider taking tritozumab into the health insurance catalogue.
【作者单位】：华中科技大学医药卫生管理学院;
【基金】：国家自然科学基金面上项目(71673095)
【分类号】：R956

【相似文献】